ArticleFrontiers in nutrition2025
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: The present study focused on the regulatory effects of aqueous extract from PLR on the asymptomatic hyperuricemia rat model, induced by potassium oxonate. Serum uric acid (SUA), serum blood urea nitrogen (BUN), creatinine (CRE), serum inflammatory factors, anthine oxidase activity, hepatic and renal tissue morphology were measured to assess the anti-hyperuricemia effect. After which, 16SrDNA sequencing and the UHPLC-Q-Orbitrap-MS/MS with network pharmacology, qRT-PCR and molecular docking were employed to elucidated the potential mechanism. Results: PLR treatment led to a significant improvement in HUA rats, including lower SUA, BUN, CRE and serum inflammatory factors (TNF- Conclusion: Our finding suggest that PLR could effectively ameliorate HUA symptoms by modulating multiple compounds, targets, and pathways. Specifically, hispidulin, cirsimaritin, galangin, and diosmetin are proposed as the key active ingredients in PLR for HUA alleviation. The primary mechanism involves inhibiting xanthine oxidase activity to reduce UA production, promoting UA excretion by restoring the abundance of intestinal flora, and eliminating the negative feedback regulatory mechanism of renal tissue. This study provided a new perspective for the precise exploitation of PLR as a functional food.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.